Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
Crinetics Pharmaceuticals (CRNX) Prices 5.63M Share Offering at $22.22/sh
-
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
-
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
-
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Crinetics Pharmaceuticals (CRNX) Prices 7.58M Share Offering of Common Stock at $19.80/sh
-
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Crinetics Pharmaceuticals (CRNX) Announces Proposed Stock Offering, Size not Disclosed
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Crinetics Pharmaceuticals to Participate in September Investor Conferences
-
Crinetics Pharmaceuticals to Participate in September Investor Conferences
-
Companies with NDRs 4/21
-
Companies with NDRs 4/19
-
Crinetics Pharmaceuticals to Participate in September Investor Conferences
-
Crinetics Pharmaceuticals to Participate in September Investor Conferences
-
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Crinetics Pharmaceuticals (CRNX) Prices 7.15M Share Common Offering at $14/Sh
-
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Crinetics Pharmaceuticals (CRNX) Announces Proposed Common Share Offering
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
-
UPDATE: Cantor Fitzgerald Starts Crinetics (CRNX) at Overweight

